Does an Increase in Serum FGF21 Level Predict 28-day Mortality of Critical Patients with Sepsis and ARDS?

Xing Li
Changsha of Traditional Chinese Medical Hospital

Hua Shen
Changsha of Traditional Chinese Medical Hospital

Tinghong Zhou
Changsha of Traditional Chinese Medical Hospital

Xiaoyu Cao
Changsha of Traditional Chinese Medical Hospital

Ying Chen
Changsha of Traditional Chinese Medical Hospital

Yan Liang
Liuzhou Traditional Chinese Medical Hospital

Ting Lu
Changsha of Traditional Chinese Medical Hospital

Jiafen He
Liuzhou Traditional Chinese Medical Hospital

Zhoulin Dou
Changsha of Traditional Chinese Medical Hospital

Chuaikai Liu
Changsha of Traditional Chinese Medical Hospital

Yong Tang
Changsha of Traditional Chinese Medical Hospital

Zexiang Zhu (zhuzexiang12@163.com)
Changsha of Traditional Chinese Medical Hospital

Research

Keywords: Mortality of Critical Patients, Sepsis, ARDS

DOI: https://doi.org/10.21203/rs.3.rs-349444/v1
Abstract

Background

Sepsis may be accompanied by acute respiratory distress syndrome (ARDS) in patients admitted to intensive care units (ICUs). It is essential to identify prognostic biomarkers in patients with sepsis and ARDS.

Objective

Determine whether changes in the level of serum fibroblast growth factor 21 (FGF21) can predict the 28-day mortality of ICU patients with sepsis and ARDS.

Methods

Consecutive sepsis patients were divided into two groups (Sepsis+ARDS and Sepsis-only), and the Sepsis+ARDS group was further classified as survivors or non-survivors. Demographic data and comorbidities were recorded. The Sequential Organ Failure Assessment (SOFA) score and serum levels of cytokines and other biomarkers were recorded 3 times after admission. Multiple Cox proportional hazards regression was used to identify risk factors associated with 28-day mortality in the Sepsis+ARDS group.

Results

The Sepsis+ARDS group had a greater baseline SOFA score and serum levels of cytokines and other biomarkers than the Sepsis-only group; the serum level of FGF21 was almost 2-fold greater in the Sepsis+ARDS group (P<0.05). Non-survivors in the Sepsis+ARDS group had an almost 5-fold greater level of FGF21 than survivors in this group (P<0.05). The serum level of FGF21 persistently increased from the baseline to the peak of shock and death in the non-survivors, but persistently decreased in survivors (P<0.05). Changes in the serum FGF21 level between different time points were independent risk factors for mortality.

Conclusion

A large increase of serum FGF21 level from baseline is associated with 28-day mortality in ICU patients with sepsis and ARDS.

1. Background

Sepsis is defined as a life-threatening organ dysfunction caused by the host's dysregulated response to an infection [1]. Sepsis may lead to acute respiratory distress syndrome (ARDS), a condition characterized by acute, diffuse, and inflammatory lung injury that leads to increased non-hydrostatic extravascular lung water, reduced lung compliance, and severe hypoxemia [2].
Despite therapeutic innovations, the mortality rate of patients with sepsis is as high as 25 to 30% [3] and the mortality rate of patients with ARDS can reach 35 to 45% [4]. Sepsis and ARDS are closely related, and most of these patients receive care in intensive care units (ICUs). Up to 50% of sepsis patients admitted to ICUs develop ARDS [5], and the mortality rate of patients with sepsis and ARDS is greater than that of patients with sepsis alone or ARDS alone [6-7]. Thus, it is essential to identify the characteristics of sepsis patients who develop ARDS after ICU admission.

Sepsis and ARDS are heterogeneous inflammatory syndromes, and certain phenotypes might be associated with clinical outcomes. Several studies reported that sepsis patients with hyper-inflammation had higher mortality rates [6-7]. Similarly, some studies showed that patients with ARDS and hypo-inflammation might have better clinical outcomes than those with ARDS and hyper-inflammation [8-9]. There is also evidence that some pro- and anti-inflammatory biomarkers have prognostic value in patients with sepsis and ARDS [10-11]. However, few studies directly examined the pro- and anti-inflammatory markers of patients with sepsis and ARDS. It is also uncertain whether the levels of pro- and anti-inflammatory cytokines are associated with the development of ARDS in patients with sepsis. Thus, it is necessary to identify novel serum biomarkers that can be used to classify disease severity in patients with sepsis and ARDS.

Fibroblast growth factor 21 (FGF21) is a peptide hormone that regulates energy homeostasis and glucose-lipid metabolism that is synthesized by the liver, adipocytes, pancreas, and brain [14]. The plasma level of FGF21 is greater in patients with metabolic disorders, such as type 2 diabetes, obesity, and mitochondrial diseases, and the level also increases during aging [15-16]. Patients with inflammatory reactions, such as sepsis, pancreatitis, and systemic inflammatory response syndrome (SIRS), have increased serum levels of FGF21 [17-18]. FGF21 apparently reduces oxidative stress by decreasing the level of reactive oxygen species (ROS), repressing nuclear factor kappa B (a pro-inflammatory factor), and reducing apoptosis [19–22]. Siahanidou et al. and our previous study demonstrated that FGF21 has value as a prognostic indicator in patients with sepsis [23-24].

However, the relationship of FGF21 with prognosis in patients with sepsis and ARDS is uncertain. In this prospective cohort study, we aimed to evaluate whether changes in the serum level of FGF21 predict 28-day mortality of ICU patients who have sepsis and ARDS.

2. Patients And Methods

2.1 Patients

This prospective cohort study included 231 consecutive patients with sepsis who were admitted to the Department of Critical Care Medicine of Changsha of Traditional Chinese Medicine Hospital (Hunan, China) between January 2019 and December 2020. Sepsis was diagnosed according to the Sepsis-3 criteria [1] and ARDS was diagnosed according to the Berlin definition [2]. All included patients were older than 18 years. The exclusion criteria were cancer, hospitalization or receipt of antibiotics during the preceding 2 weeks, and re-admission to the ICU.
All eligible patients were divided into a Sepsis-only group (patients who met the Sepsis-3 criteria and had no evidence of ARDS) and a Sepsis+ARDS group. The Sepsis+ARDS group was further divided into a survival group (patients who survived 28 days after initial diagnosis) and a non-survival group (patients who died within 28 days after diagnosis).

Demographic data (including age and gender) and medical history (including cardiovascular diseases, diabetes mellitus, chronic renal failure, and chronic obstructive pulmonary disease) were recorded. Laboratory values, hemodynamic parameters, ventilator settings, and medications were recorded at disease inception, during the worst period of disease, and during the recovery period. Sequential Organ Failure Assessment (SOFA) scores were calculated. The main clinical outcome measure was 28-day mortality.

Each patient received standard treatment during the ICU stay. This study was approved by the Ethics Committee of Changsha of Traditional Chinese Medicine Hospital and informed consent was obtained from all patients or their guardians.

2.2 Cytokine measurements

Blood samples were collected within 24 h after diagnosis, during the worst period of disease, and during the recovery period. The serum levels of FGF21, interleukin 6 (IL-6), IL-10, tumor necrosis factor α (TNFα), procalcitonin (PCT), and C reactive protein (CRP) were determined using enzyme-linked immunosorbent assays (ELISAs) from Abcam (USA) according to the manufacturer's instructions. Routine blood tests and blood gas analyses were performed in the hospital’s central laboratory.

2.3 Statistical analysis

The normality of the distribution of a quantitative variable was tested using the Kolmogorov-Smirnov test (P > 0.10). Normally distributed data are expressed as means and standard deviations (SDs), and non-normally distributed data as medians and interquartile ranges (IQRs). Qualitative data are presented as number (%). For continuous variables, two-group comparisons were performed using Student’s t-test or the Mann-Whitney U test, depending on the normality of the distribution. For categorical variables, the Chi-square test, Fisher’s exact test, or McNemar’s test was used as appropriate. Spearman’s correlation coefficient (ρ) was used to identify correlations between FGF21 level and other clinical variables. The Hotelling T^2 test was used to identify the significance of changes in the level of serum FGF21 and other markers.

To identify the risk factors for 28-day mortality of patients in the Sepsis+ARDS group, multiple Cox proportional hazards regression analyses were performed to measure the effects of different variables at three key times: (1) ICU admission; (2) peak of shock; and (3) before death or ICU discharge. The value of each measured parameter (P) is expressed as “P_t”, where ‘t’ is the measurement time (1, 2, or 3); the change in a parameter between two times is expressed as “ΔP_{t1-t2}”, where ‘t1’ and ‘t2’ are the measurement times; and the percentage change in a parameter between two times is expressed as
All statistical analyses were performed using SPSS version 24.0 software (IBM SPSS, USA). A two tailed P value below 0.05 was considered significant.

3. Results

3.1 Comparison of the Sepsis and Sepsis+ARDS groups

We initially compared the clinical characteristics of patients in the Sepsis-only and the Sepsis+ARDS groups (Table 1). The Sepsis+ARDS group had a greater respiratory rate, a lower PaO$_2$/FiO$_2$, a greater SOFA score, and higher levels of lactate (LAC), procalcitonin (PCT), C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor α (TNFα), IL-10, and FGF21 (all P < 0.05). The serum level of FGF21 was almost two-times greater in the Sepsis+ARDS group.

3.2 Comparison of survivors and non-survivors in the Sepsis+ARDS group

The survivors and non-survivors in the Sepsis+ARDS group had similar age, gender, and underlying diseases (Supplementary Table 1). At baseline, the non-survivors had a significantly lower mean arterial pressure, hematocrit, and Glasgow Coma Scale (GCS) score; greater heart rate, body temperature, and SOFA score; and greater serum levels of creatinine, LAC, PCT, CRP, IL-6, TNFα, IL-10 (Table 2; all P < 0.05). The serum level of FGF21 was almost five-times greater in the non-survivors.

3.3 Dynamics of FGF21 in the Sepsis+ARDS group

We recorded the changes of cytokines and other biomarkers while patients in the Sepsis+ARDS group were in the ICU (Fig. 1). The serum level of FGF21 persistently increased from baseline in the non-survivors, but gradually decreased in the survivors (both P < 0.05). In addition, pro-inflammatory biomarkers (CRP, PCT, TNF-α, IL-6,) and SOFA score also increased in the non-survivors, and decreased in the survivors (all P < 0.05).

3.4 Correlation of FGF21 level with clinical indicators and cytokine levels

Analysis of patients in the Sepsis+ARDS group at baseline indicated the serum level of FGF21 was positively correlated with SOFA score and the serum levels of PCT, CRP, IL-6, IL-10, LAC, and TNF-α in these patients (Table 3, all P < 0.05).

3.5 Risk factors for 28-day mortality in Sepsis+ARDS patients based on measurements at 3 crucial time points

We initially analyzed variables associated with 28-day mortality based on measurements at 24 to 48 h after ICU admission (Table 4-1). The results indicated that serum FGF21 level, SOFA score, and serum level of CRP were independent risk factors for 28-day mortality (all P < 0.05).
We then analyzed variables associated with 28-day mortality based on initial measurements and measurements at the peak of shock (Table 4-2). The results indicated that the $\Delta$SOFA$_{2-1}$, FGF21$_2$, and $\Delta$FGF21%$_{2-1}$ were independent risk factors for 28-day mortality (all $P < 0.05$).

We also analyzed variables associated with 28-day mortality based on measurements performed at 2 to 3 days before death or ICU discharge, measurements at the peak of shock, and initial measurements (Table 4-3). The results indicated that $\Delta$SOFA$_{3-1}$, $\Delta$FGF21%$_{3-1}$, $\Delta$ LAC%$_{3-1}$, and baseline CRP$_1$ were independent risk factors for 28-day mortality (all $P < 0.05$).

**Discussion**

In this study, we found that the serum FGF21 level at baseline was greater in ICU patients who had sepsis and ARDS than in those who had sepsis alone. Furthermore, non-survivors in the Sepsis+ARDS group had persistently increasing levels of FGF21 during their ICU stays, but survivors in the Sepsis+ARDS group had persistently declining levels. Notably, our Cox proportional hazards model indicated that an increase in the serum level of FGF21 from the baseline was a significant risk factor for 28-day mortality in the Sepsis+ARDS group. To our best knowledge, this is the first study to identify the prognostic value of dynamic changes in the serum level of FGF21 in patients with sepsis and ARDS.

Previous studies demonstrated that the serum level of FGF21 was greater in adults and newborns who had sepsis [23-24]. Our previous study demonstrated that the serum level of FGF21 was positively associated with serum inflammation biomarkers, including PCT, CRP, IL-6, and TNF$\alpha$ [24]. Patients with sepsis and ARDS have a greatly increased inflammatory state. Thus, it is not surprising that the serum level of FGF21 was greater in patients with sepsis and ARDS. Moreover, we found that the baseline FGF21 level correlated with the baseline levels of multiple inflammatory markers (Table 3).

Elevation of inflammatory and anti-inflammatory biomarkers can occur concurrently during the early phase of sepsis [25]. Previous studies reported that FGF21 had anti-inflammatory effects during sepsis [26]. The present study, which compared patients with sepsis alone vs. sepsis and ARDS, identified much higher levels of serum FGF21 and pro-inflammatory factors (PCT, CRP, IL-6, and TNF$\alpha$) in the Sepsis+ARDS group. This suggests a more intense interaction between pro-inflammatory and anti-inflammatory factors in patients who have sepsis and ARDS.

Our analysis of disease progression in patients with sepsis and ARDS indicated the non-survivors had continuously increased serum levels of FGF21, and this was accompanied by persistent increases in the levels of multiple pro-inflammatory cytokines. In contrast, the survivors had gradually decreased levels of FGF21 and of pro-inflammatory cytokines. The presence of higher levels of pro- and anti-inflammatory biomarkers in the non-survivors is consistent with the presence of increased physiological stress.

Because the dynamic changes of pro- and anti-inflammatory markers appeared to be of vital importance in the progression of patients with sepsis and ARDS, we were interested in the following question: Which parameters can be used to predict the mortality of patients with sepsis and ARDS? Thus, we used Cox
regression analysis to assess the prognostic value of biomarkers that were measured at admission to the ICU, at the peak of shock, and before death (non-survivors) or before ICU discharge (survivors). Our measurements at admission indicated that increased FGF21, LAC, and SOFA score were associated with poor prognosis in patients with sepsis and ARDS. This result is consistent with results from our previous study [24].

Our measurements at the peak time of shock (typically 1 week after ICU admission) indicated that the percentage increase in the FGF21 from baseline ($\Delta$FGF21$\%_{2-1}$) and the change of SOFA score from baseline ($\Delta$SOFA$\%_{2-1}$) were best predictors of poor prognosis. In this model, the $\Delta$FGF21$\%_{1-2}$ value had a much greater HR (15.269 [95% CI: 1.622~143.712] vs. 1.247 [95% CI: 1.096~1.418]). In other words, based on measurements at baseline and the peak of shock, the percentage increase of FGF21 was the best single predictor of poor prognosis in patients with sepsis and ARDS. These large changes in the serum level of FGF21 from admission to the peak of shock reflect the dynamics of pro- and anti-inflammatory factors in patients with sepsis and ARDS.

We also analyzed the relationship of the final clinical measurements (before death or ICU discharge) with patient prognosis. We found that the $\Delta$FGF21$\%_{3-1}$, $\Delta$LAC$\%_{3-1}$, and $\Delta$SOFA$\%_{3-1}$, and CRP$\%_1$ were significant prognostic factors. Notably, $\Delta$FGF21$\%_{3-1}$ was best predictor of poor prognosis (HR = 25.760 [95% CI: 1.482~447.610]). This confirms that a large increase in the serum level of FGF21, either between the first and second measurements or between the first and third measurements, was strongly associated with 28-day mortality in patients with sepsis and ARDS. At the physiological level, this may be attributed to the anti-inflammation, anti-apoptotic, and anti-oxidative effect of FGF12 during sepsis.

**Limitations**

First, this was a single-center study, and the total number of patients with sepsis and ARDS was relatively small. However, we have been pursuing this topic and collecting the records of sepsis patients for several years. A large and multi-center study should be performed to verify our observations. Second, because pro-inflammatory and anti-inflammatory factors both increased during sepsis, it is possible that other unmeasured anti-inflammatory cytokines might have also played a crucial role. We are currently analyzing the prognostic value of other anti-inflammatory biomarkers in sepsis patients, and plan further comparisons of their functions in patients with sepsis and ARDS. Third, some sepsis patients experience a hypo-inflammation phenotype. Most of our patients experienced hyper-inflammation, and this may be attributable to our exclusion criteria, such as exclusion of patients with cancer. The effect of changes in the serum level of FGF21 on the prognosis of patients with sepsis and ARDS who have hypo-inflammation is a topic that needs further study.

**Conclusion**

An increase in the serum level of FGF21 after ICU admission of patients who have sepsis and ARDS is associated with a significantly increased risk of 28-day mortality.
Abbreviations

ARDS: acute respiratory distress syndrome
ICUs: intensive care units
FGF21: fibroblast growth factor 21
SOFA: Sequential Organ Failure Assessment
IL-6: interleukin 6
IL-10: interleukin 10
TNFα: tumor necrosis factor α
PCT: procalcitonin
CRP: C reactive protein
LAC: lactate
GCS: Glasgow Coma Scale

Declarations

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Changsha of Traditional Chinese Medicine Hospital.

Consent for publication
An informed consent form was obtained from all the patients or their guardians.

Availability of data and material
Data will not be shared with a reason.

Funding:
This study was sponsored by the Natural Science Foundation of Hunan Province, China (No.2019JJ80051 and No.2019JJ80061).

Competing interests
The authors declare that they have no competing interests.
Authors’ contributions

YL, TL, JFH, CKL, ZLD and YC finished clinical studies and collected primary data. THZ and XYC analyzed the data. XL finished the experiment, and performed statistic analysis, and wrote the manuscript. HS participated in the design of the study and edited the manuscript. YT and ZXZ conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

[1] M. Singer, C.S. Deutschman, C.W. Seymour, M. Shankar-Hari, D. Annane, M. Bauer, et al., The third international consensus definitions for sepsis and septic shock (sepsis-3), JAMA 315 (2016) 801–810.

[2] Ranieri V Marco, Rubenfeld Gordon D, Thompson B Taylor, et al. Acute respiratory distress syndrome: the Berlin Definition. [J]. JAMA, 2012, 307(23).

[3] Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis [J]. BMJ, 2007, 335(7625):879-883.

[4] Bellani G, Laffey J G, Pham, Tài, et al. Epidemiology, Patterns of Care and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries [J]. JAMA, 2016, 315(8):788.

[5] Hudson L D. Clinical risks for development of the acute respiratory distress syndrome. [J]. American Journal of Respiratory & Critical Care Medicine, 1995, 151.

[6] Hatfield K M , Dantes R B , Baggs J , et al. Assessing Variability in Hospital-Level Mortality Among U.S. Medicare Beneficiaries With Hospitalizations for Severe Sepsis and Septic Shock*[J]. Critical Care Medicine, 2018, 46(11):1753-1760.

[7] Sevransky J E, Martin G S, Carl Shanholtz, et al. Mortality in sepsis versus non-sepsis induced acute lung injury [J]. Critical Care, 2009, 13(5):R150-R150.

[8]Ricarte-Bratti Juan Pablo, Brizuela Nilda Y, et al. IL-6, MMP 3 and prognosis in previously healthy sepsis patients. [J]. Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2017, 74(2).

[9]Anderson B J, Calfee C S, Liu K D, et al. Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study [J]. Critical Care, 2019, 23(1).

[10]Calfee C S , Delucchi K , Parsons P E , et al. Latent Class Analysis of ARDS Sub phenotypes: Analysis of Data From Two Randomized Controlled Trials[J]. Lancet Respiratory Medicine, 2014, 2(8):611.
[11] Bos L D, Schouten L R, Van Vught L A, et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis [J]. Thorax, 2017: thoraxjnl-2016-209719.

[12] Spadaro S, Park M, Turrini C, et al. Biomarkers for Acute Respiratory Distress syndrome and prospects for personalized medicine [J]. Journal of Inflammation, 2019, 16(1).

[13] Oberholzer A, Souza S M, Tschoeke S K, et al. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis[J]. Shock, 2005, 23(6):488-493.

[14] Xie T, Leung P S. Fibroblast growth factor 21: a regulator of metabolic disease and health span [J]. American Journal of Physiology Endocrinology & Metabolism, 2017 Sep 1; 313(3):E292-E302.

[15] Staiger H, Keuper M, Berti L, et al. Fibroblast Growth Factor 21 - Metabolic Role in Mice and Men [J]. Endocrine Reviews, 2017.

[16] Tezze, Caterina, Romanello, Vanina, Desbats, Maria Andrea, et al. Age-Associated Loss of OPA1 in Muscle Impacts Muscle Mass, Metabolic Homeostasis, Systemic Inflammation, and Epithelial Senescence [J]. Cell Metabolism, 2017:S1550413117302279.

[17] Garini, K., Drifte, G., Dunn-Siegrist, I., Pugin, J., & Jornayvaz, F. R. Increased FGF21 plasma levels in humans with sepsis and sirs. Endocrine Connections, 2(3), 146-153.

[18] Shenoy V K, Beaver K M, Fisher F M, et al. Elevated Serum Fibroblast Growth Factor 21 in Humans with Acute Pancreatitis [J]. PLoS ONE, 2016, 11(11):e0164351.

[19] A. Planavila, I. Redondo-Angulo, F. Ribas, G. Garrabou, J. Casademont, M. Giralt, et al., Fibroblast growth factor 21 protects the heart from oxidative stress, Cardiovasc. Res. 106 (2015) 19–31.

[20] Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice.[J]. Nature Communications, 2013, 4(3):2019.

[21] E. Hondares, R. Iglesias, A. Giralt, F.J. Gonzalez, M. Giralt, T. Mampel, et al., Thermogenic activation induces FGF21 expression and release in brown adipose tissue, J. Biol. Chem. 286 (2011) 12983–12990.

[22] Y. Jeanson, F. Ribas, A. Galinier, E. Arnaud, M. Ducos, M. Andre, et al., Lactate induces FGF21 expression in adipocytes through a p38-MAPK pathway, Biochem. J. 473 (2016) 685–692.

[23] Siahanidou T, Margeli A, Bourika V, et al. Association of fibroblast growth factor 21 plasma levels with neonatal sepsis: preliminary results [J]. Clinical Chemistry & Laboratory Medicine, 2019, 57(5):e83-e85.

[24] Xing L, Zexiang Z, Tinghong Z, et al. Early increases in serum FGF21 levels predict mortality of septic patients [J]. Cytokine, 2018 Nov; 111:428-433.

[25] Tamayo E, Fernandez A, Almansa R, Carrasco E, Heredia M, Lajo C, et al. Pro- and
anti-inflammatory responses are regulated simultaneously from the first moments of septic shock. Eur Cytokine Netw. 2011; 22:82-7.

[26] Feingold KR, Grunfeld C, Heuer JG, Gupta A, Cramer M, Zhang T, et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology. 2012; 153:2689-700.

Tables

Table 1. Baseline clinical characteristics of patients in the Sepsis+ARDS group and the Sepsis-only group.*
| Parameter                          | Sepsis+ARDS (n=161) | Sepsis-only (n=69) | P value |
|-----------------------------------|----------------------|--------------------|---------|
| Mean arterial pressure (mmHg)    | 80±19                | 89±15              | 0.106   |
| Respiratory rate (per minute)    | 24(12~48)            | 20(12~30)          | 0.006   |
| Heart rate (bpm)                 | 106±25               | 97±12              | 0.068   |
| Temperature (°C)                 | 37.5±1.3             | 37.4±0.4           | 0.791   |
| White blood count (10⁹/L)        | 14.4(0.26~54.24)     | 13.37(3.29~42.35)  | 0.690   |
| Platelet count (10⁹/L)           | 168(17~527)          | 135(55~420)        | 0.367   |
| Hematocrit (%)                   | 32.0±6.8             | 32.0±5.7           | 0.432   |
| PaO₂/FiO₂ (mmHg)                 | 172.3±60.8           | 348.8±135.4        | 0.000   |
| Total bilirubin (μmmol/L)        | 18.4(4.0~124.7)      | 17.6(7.3~83.35)    | 0.151   |
| Creatinine (μmmol/L)             | 99.9(33.7~1477.9)    | 76.2(32.9~684.6)   | 0.079   |
| LAC (mmol/L)                     | 2.7(0.5~18.0)        | 2.1(0.7~5.6)       | 0.000   |
| GCS score                        | 11(3~15)             | 11(3~15)           | 1.000   |
| SOFA score                       | 7(2~21)              | 4(2~13)            | 0.000   |
| CRP (mg/L)                       | 113.1(9.77~468.0)    | 71.4(6.8~498.0)    | 0.000   |
| PCT (ng/mL)                      | 6.57(0.15~200.0)     | 1.89(0.05~21.0)    | 0.002   |
| IL-6 (pg/mL)                     | 113.4(2.93~498.1)    | 56.7(4.0~345.6)    | 0.001   |
| TNF-α (pg/mL)                    | 14.9(5.8~215.4)      | 11.9(5.9~46.3)     | 0.000   |
| IL-10 (pg/mL)                    | 154.6(10.7~798.7)    | 76.9(7.1~496.8)    | 0.009   |
| FGF21 (pg/mL)                    | 1108.3 (32.3~6978.5) | 533.0 (41.1~3652.5)| 0.000   |

*Here and below: Values are expressed as mean ± SD or median (IQR); ARDS, acute respiratory distress syndrome; bpm, beats per minute; GCS, Glasgow coma scale; SOFA, sequential organ failure assessment; PCT, procalcitonin; CRP, C-reactive protein; IL, interleukin; LAC, lactate; TNF, tumor necrosis factor; FGF, fibroblast growth factor.

**Table 2. Baseline clinical characteristics of patients in the Sepsis+ARDS group who were survivors and non-survivors.**
| Parameter                          | Non-survivors (n=42) | Survivors (n=119) | P value |
|-----------------------------------|----------------------|-------------------|---------|
| Mean arterial pressure (mmHg)     | 68(35~116)           | 87(48~120)        | 0.000   |
| Respiratory rate (per minute)     | 24(12~40)            | 22(13~38)         | 0.125   |
| Heart rate (bpm)                  | 110±33               | 98±20             | 0.022   |
| Temperature (°C)                  | 38.1±1.4             | 37.2±0.8          | 0.019   |
| White blood count (10⁹/L)         | 15.0±6.6             | 14.3±7.2          | 0.682   |
| Platelet count (10⁹/L)            | 131(17~364)          | 178(35~473)       | 0.055   |
| Hematocrit (%)                    | 31.3±7.0             | 35.4±5.7          | 0.050   |
| PaO₂/FiO₂ (mmHg)                  | 152.1±55.7           | 164.6±54.5        | 0.021   |
| Total bilirubin (μmmol/L)         | 19.5(4.6~124.7)      | 19.0(4.8~98.5)    | 0.183   |
| Creatinine (μmmol/L)              | 144.0(44.9~1477.9)   | 96.4(33.7~507.6)  | 0.009   |
| Lactate (mmol/L)                  | 3.7(0.9~18.0)        | 2.7(1.2~5.6)      | 0.000   |
| GCS score                         | 9(3~15)              | 11(3~15)          | 0.000   |
| SOFA score                        | 11(3~21)             | 6(2~18)           | 0.000   |
| CRP (mg/L)                        | 134.9(18.6~468.0)    | 100.7(9.8~200.0)  | 0.000   |
| PCT (ng/mL)                       | 16.96(1.70~200.00)   | 3.07(0.15~200.0)  | 0.000   |
| IL-6 (pg/mL)                      | 367.7(37.3~498.2)    | 89.6(2.9~462.6)   | 0.000   |
| TNF-α (pg/mL)                     | 63.9(11.1~215.4)     | 12.3(5.8~102.1)   | 0.000   |
| IL-10 (pg/mL)                     | 597.6(68.0~798.7)    | 108.6(10.7~657.9) | 0.000   |
| FGF21 (pg/mL)                     | 3574.7               | 986.6             | 0.000   |
|                                  | (327.3~6978.5)       | (32.3~6121.3)     |         |

Table 3. Correlation of baseline FGF21 level with SOFA score and biomarkers in the Sepsis+ARDS group.
Table 4-1. Cox proportional hazards model for mortality in the Sepsis+ARDS group based on measurements at baseline (1).

| Parameter | Spearman’s ρ | P value |
|-----------|--------------|---------|
| SOFA      | 0.338        | 0.000   |
| IL-6      | 0.550        | 0.000   |
| TNFα      | 0.571        | 0.000   |
| IL-10     | 0.634        | 0.000   |
| PCT       | 0.368        | 0.000   |
| CRP       | 0.217        | 0.000   |
| LAC       | 0.307        | 0.000   |

Here and below: NA, not applicable.

| Variable | Multiple Cox model |
|----------|--------------------|
|          | HR (95% CI)        | P value  |
| SOFA₁    | 1.200 (1.079~1.334) | 0.001    |
| FGF21₁   | 1.000 (1.000~1.001) | 0.000    |
| CRP₁     | 1.005 (1.001~1.010) | 0.025    |
| IL-6₁    | NA                 | 0.309    |
| TNFα₁    | NA                 | 0.089    |
| IL-10₁   | NA                 | 0.958    |
| PCT₁     | NA                 | 0.418    |
| LAC₁     | NA                 | 0.873    |

Here and below: NA, not applicable.

Table 4-2. Cox proportional hazards model for mortality in the Sepsis+ARDS group based on measurements at the peak of shock (2) and at baseline (1).*
| Variable         | Multiple Cox model |
|------------------|--------------------|
|                  | HR (95% CI)        | P value |
| SOFA<sub>1</sub> | 1.247 (1.096~1.418)| 0.001   |
| ∆SOFA<sub>2-1</sub> | NA           | 0.692   |
| ∆SOFA%<sub>2-1</sub> | NA           | 0.617   |
| FGF21<sub>1</sub> | NA           | 0.053   |
| FGF21<sub>2</sub> | 1.001 (1.000~1.001)| 0.000   |
| ∆FGF21%<sub>2-1</sub> | 15.269 (1.622~143.712)| 0.017   |
| CRP<sub>1</sub>   | NA           | 0.566   |
| CRP<sub>2</sub>   | NA           | 0.751   |
| ∆ CRP%<sub>2-1</sub> | NA           | 0.752   |
| IL-6<sub>1</sub>  | NA           | 0.700   |
| IL-6<sub>2</sub>  | NA           | 0.498   |
| ∆IL-6%<sub>2-1</sub> | NA           | 0.303   |
| TNFα<sub>1</sub>  | NA           | 0.456   |
| TNFα<sub>2</sub>  | NA           | 0.440   |
| ∆TNFα%<sub>2-1</sub> | NA           | 0.137   |
| IL-10<sub>1</sub> | NA           | 0.259   |
| IL-10<sub>2</sub> | NA           | 0.478   |
| ∆IL-10%<sub>2-1</sub> | NA           | 0.087   |
| PCT<sub>1</sub>   | NA           | 0.882   |
| PCT<sub>2</sub>   | NA           | 0.717   |
| ∆PCT%<sub>2-1</sub> | NA           | 0.896   |
| LAC<sub>1</sub>   | NA           | 0.730   |
| LAC<sub>2</sub>   | NA           | 0.652   |
|                   | NA           | 0.812   |
Here and below: the difference in the value of a parameter (P) at different times is expressed as “ΔP_{t1-t2}”, where ‘t1’ and ‘t2’ are the measurement times; and the percentage change in a parameter at different times is expressed as ΔP_{%t1-t2}.

Table 4-3. Cox proportional hazards model for mortality in the Sepsis+ARDS group based on at measurements before death or ICU discharge (3), at the peak of shock (2), and at baseline (1).
| Variable     | Multiple Cox model |          |
|--------------|--------------------|----------|
|              | P value            | HR (95% CI) |
| SOFA\(_1\)   | NA                 | 0.664    |
| SOFA\(_2\)   | NA                 | 0.735    |
| **SOFA\(_3\)** | **0.019**          | **1.148 (1.023~1.289)** |
| ΔSOFA\(_{%2-1}\) | NA                 | 0.399    |
| ΔSOFA\(_{%3-2}\) | NA                 | 0.955    |
| ΔSOFA\(_{%3-1}\) | NA                 | 0.625    |
| FGF21\(_1\)  | NA                 | 0.294    |
| FGF21\(_2\)  | NA                 | 0.197    |
| FGF21\(_3\)  | NA                 | 0.384    |
| ΔFGF21\(_{%2-1}\) | NA                 | 0.272    |
| ΔFGF21\(_{%3-2}\) | NA                 | 0.413    |
| **ΔFGF21\(_{%3-1}\)** | **0.026**          | **25.760 (1.482~447.610)** |
| CRP\(_1\)    | **0.003**          | **1.008 (1.003~1.014)** |
| CRP\(_2\)    | NA                 | 0.476    |
| CRP\(_3\)    | NA                 | 0.335    |
| ΔCRP\(_{%2-1}\) | NA                 | 0.210    |
| ΔCRP\(_{%3-2}\) | NA                 | 0.326    |
| ΔCRP\(_{%3-1}\) | NA                 | 0.426    |
| IL-6\(_1\)   | NA                 | 0.139    |
| IL-6\(_2\)   | NA                 | 0.264    |
| IL-6\(_3\)   | NA                 | 0.310    |
| ΔIL-6\(_{%2-1}\) | NA                 | 0.104    |
| ΔIL-6\(_{%3-2}\) | NA                 | 0.416    |
| NA           | NA                 | 0.155    |
|                |     |     |
|----------------|-----|-----|
| $\Delta IL-6\%_{3-1}$ |     |     |
| $\Delta TNF\alpha_{2-1}$ |     |     |
| $\Delta TNF\alpha_{3-2}$ |     |     |
| $\Delta TNF\alpha_{3-1}$ |     |     |
| $\Delta IL-10\%_{2-1}$ |     |     |
| $\Delta IL-10\%_{3-2}$ |     |     |
| $\Delta IL-10\%_{3-1}$ |     |     |
| $\Delta PCT\%_{2-1}$ |     |     |
| $\Delta PCT\%_{3-2}$ |     |     |
| $\Delta PCT\%_{3-1}$ |     |     |
| $\Delta LAC\%_{2-1}$ |     |     |
| $\Delta LAC\%_{3-2}$ |     |     |
| $\Delta LAC\%_{3-1}$ | 0.030 | 1.512 (1.041~2.196) |
Figure 1

Levels of different laboratory and clinical parameters in survivors and non-survivors of Sepsis+ARDS at ICU admission (time-1), peak of shock (time-2), and before death or ICU discharge (time-3).